PIA
TCRT icon

Piedmont Investment Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Piedmont Investment Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15
Closed -$7K – 2136
2018
Q2 		$7K Buy
+15
New +$9.51K ﹤0.01% 1989

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Piedmont Investment Advisors's TCRT Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2018, closing a stake of 15 shares — an estimated $7K sold.

Piedmont Investment Advisors first reported a position in TCRT in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 131 funds tracked by Wall St. Rank hold TCRT as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Alaunos Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 15 Alaunos Therapeutics shares in Q3 2018, an estimated $7K.
  • Piedmont Investment Advisors first reported a position in Alaunos Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Alaunos Therapeutics position peaked at $7K in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.